Parabilis Medicines
PBLS
28.82
-0.04
-0.14%
Parabilis Medicines
US · PBLS
#2366 by market cap
Listed 2026
28.82
-0.04
-0.14%
Live - 5344 symbols - heartbeat 92s ago
· 2026-10-08 08:37
Pre-market
28.99
+0.59%
After-hours
28.82
0.00%
- Market cap
- 3.56B
- P/E (TTM)i
- -15.17
- P/Bi
- 3.40
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on PBLS?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 25.30M | 26.50M |
| Research & development | 100.83M | 125.58M |
| Operating profit | -126.13M | -152.08M |
| Pretax profit | -117.91M | -145.89M |
| Tax | -- | -- |
| Net profit | -117.91M | -145.89M |
| Basic EPS | -2 | -2 |
| Diluted EPS | -2.01 | -1.81 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | 0 | -- | 148.00K |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 6.34M | 6.39M | 9.70M | 11.66M |
| Research & development | 33.91M | 30.13M | 37.75M | 39.38M |
| Operating profit | -40.24M | -36.52M | -47.45M | -50.89M |
| Pretax profit | -38.33M | -34.81M | -45.32M | -52.46M |
| Tax | -- | -- | -- | -- |
| Net profit | -38.33M | -34.81M | -45.32M | -52.46M |
| Basic EPS | -1 | -1 | -1 | -2 |
| Diluted EPS | -0.60 | -0.56 | -0.56 | -2.32 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 92.21M | 29.36M |
| Cash & ST investments | 87.98M | 27.71M |
| Inventory | -- | -- |
| Total assets | 149.25M | 80.82M |
| Total current liabilities | 32.41M | 56.79M |
| Short-term debt | 9.38M | 20.89M |
| Long-term debt | 12.79M | -- |
| Total liabilities | 92,814,000.00 | 97,344,000.00 |
| Total equity | 56.44M | -16.52M |
| Retained earnings | -395.62M | -541.50M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 332.07M | 1.13B |
| Cash & ST investments | -- | -- | 329.04M | 1.12B |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 384.17M | 1.18B |
| Total current liabilities | -- | -- | 54.24M | 62.84M |
| Short-term debt | -- | -- | 17.43M | 13.97M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 139,953,000.00 | 127,528,000.00 |
| Total equity | -- | -- | 244.22M | 1.05B |
| Retained earnings | -- | -- | -586.82M | -639.28M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -103.61M | -123.71M |
| Depreciation & amortization | 2.10M | 2.50M |
| Free cash flow | -104.49M | -124.02M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 50.14M | 30.57M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -34.15M | -31.09M | -49.20M | -3.62M |
| Depreciation & amortization | 654.00K | 618.00K | 606.00K | 593.00K |
| Free cash flow | -34.23M | -31.11M | -49.57M | -4.24M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 89.96M | 83.25M | 331.89M | 1.09B |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -108.19 | -162.50 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 2.84 | 0.52 |
| Quick ratioi | 2.73 | 0.49 |
| Debt / assetsi | 44.35 | 72.63 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -78.35 | -94.85 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -22.11 |
| ROA %i | -- | -- | -54.59 | -19.71 |
| ROIC %i | -- | -- | -- | -21.74 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -114,393.92 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 6.12 | 17.91 |
| Quick ratioi | -- | -- | 6.07 | 17.83 |
| Debt / assetsi | -- | -- | 13.83 | 4.04 |
| LT debt / equityi | -- | -- | -- | 3.20 |
| Interest coveragei | -- | -- | -107.04 | -137.76 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing Helicon medicines targeting historically undruggable proteins100.00%
Quote time 2026-10-08 08:37:33 · For reference only, not investment advice and not tailored to your situation.